Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Ho

Interventional Pain Medicine Fullerton, CA Medical Doctor

NPI 1285856609 CMS profile 58185

150 Laguna Rd Ste A, Fullerton, CA 92835

Open in the dashboard

General payments

$9,600

306 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Ho of Fullerton, CA is reported in the CMS Open Payments database as having received $9,600 across 306 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $419 16
2024 General $1,720 25
2023 General $1,153 52
2022 General $1,105 36
2021 General $2,363 45
2020 General $793 51
2019 General $2,046 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Ho
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Joseph Ho were reported at $419. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Joseph Ho Interventional Pain Medicine median Middle half National median
2019 $2,046 $684 $216–$2,079 $163
2020 $793 $382 $122–$1,109 $114
2021 $2,363 $552 $167–$1,554 $132
2022 $1,105 $605 $187–$1,924 $149
2023 $1,153 $671 $195–$1,915 $160
2024 $1,720 $684 $206–$1,837 $164
2025 $419 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,551 48 payments
  2. IBSA Pharma Inc. $1,518 22 payments
  3. Biohaven Pharmaceuticals, Inc. $1,500 9 payments
  4. Medtronic USA, Inc. $452 20 payments
  5. Collegium Pharmaceutical, Inc. $448 25 payments
  6. Daiichi Sankyo Inc. $443 25 payments
  7. Boston Scientific Corporation $377 15 payments
  8. Abbott Laboratories $351 6 payments
  9. AbbVie, Inc. $325 14 payments
  10. Lilly USA, LLC $307 13 payments
  11. Other $2,328 109 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,998 300 payments
  2. Consulting Fee $2,400 2 payments
  3. Travel and Lodging $202 4 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $1,712 15 payments
  2. Licart $1,518 22 payments
  3. INTELLIS ADAPTIVESTIM $1,146 39 payments
  4. Morphabond ER $443 25 payments
  5. XTAMPZA $313 18 payments
  6. INTELLIS $312 14 payments
  7. Proclaim Family of SCS IPGs $292 4 payments
  8. GENERAL PAIN MANAGEMENT $252 8 payments
  9. SPRINT PNS System $236 3 payments
  10. Tirosint $226 19 payments
  11. Other $3,873 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,974

Median for Interventional Pain Management: 1,220

Drug cost

$87,622

Median for Interventional Pain Management: $39,344

Branded share of claims

26.5%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 447 $11,917
Lyrica Pregabalin Brand 13 $8,969
Lidocaine Generic 47 $8,256
Movantik Naloxegol Oxalate Brand 13 $6,115
Diclofenac Sodium Generic 121 $5,489
Gabapentin Generic 385 $5,432
Buprenorphine Generic 46 $4,758
Fentanyl Generic 35 $4,138
Belbuca Buprenorphine Hcl Brand 13 $4,102
Celecoxib Generic 130 $4,101

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$178,401

Of which drugs: $6,807

Medicare patients

219

Average age 74

Services billed

11,313

146 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Osteoporosis 35%
Depression 32%
Chronic kidney disease 31%
Ischemic heart disease 30%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 78 7,453 $755
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 81 534 $154
Injection, methylprednisolone acetate, 40 mg J1030 Office 22 26 $126
Injection, methylprednisolone acetate, 80 mg J1040 Office 15 15 $115
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 380 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Licart
  • IBSA Pharma Inc. $1,321
$1,321 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $43
$43 13 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $37
$37 — —
NURTEC ODT
  • PFIZER INC. $37
$37 — —
ZAVZPRET
  • PFIZER INC. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

306 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record